Jefferies Reiterates Buy Rating on Novavax (NVAX): "capital-light adjuvant platform with improving line-of-sight"
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $25.00 price target on Novavax (NASDAQ: NVAX)The analyst commented, "We caught ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
